期刊文献+

终末期肝病模型判断原发性肝癌患者预后的价值 被引量:7

Prognostic value of the model for end-stage liver disease in patients with primary hepatic cancer
下载PDF
导出
摘要 目的:研究终末期肝病模型(model for end-stage liver disease,MELD)判断原发性肝癌(primary hepatic cancer,PHC)患者病情和预后的可行性。方法:选择原发性肝癌患者的资料进行登记和随访,最后选择具有完整记录资料和随访结果的303例原发性肝癌患者进行分析,根据MELD公式计算每个患者的MELD值,并同时计算Child-Turcotte-Pugh(CTP)评分(CS)和分级(CC)。运用接受者运行曲线(ROC曲线)及其曲线下面积(AUC)比较MELD、CTP评分和分级判断肝硬化患者生存3个月、1年等不同时间的准确性。运用Kaplan-Meier生存分析,比较不同MELD值时患者的生存率变化。结果:MELD判断患者生存3个月和1年时间的ROC曲线AUC分别为0·85和0·78,CS分别是0·88和0·76,CC分别是0·81和0·73。3种模型判断患者生存不同时间的ROC曲线AUC差异无统计学意义,P>0·05。当MELD值>20时,门脉高压并发症的发生率明显高于<20组,患者生存时间和生存率明显下降,P=0·000。结论:MELD同CTP评分和分级一样,在判断PHC患者短期预后方面是一个较好的指标。 OBJECTIVE.. To evaluate the predicting abilities of the model for end-stage liver disease (MELD) to predict prognosis in pationts with primary bepatic cancer. METHODS: A cohort of 303 patients with primary hepatic cancer were retrospectively studied and followed up at least for one year. MELD score was calculated for each patient according to the modified formula by Kamath P. S. , Child-Turcotte-Pugh (CTP) score and classification were calculated at the same time. The area under the receiver operating characteristic (ROC) curve (AUC) was used to compare MELD and CTP score and classification in predicting accuracy for different sur- vival periods. Kaplan-Meier survival analysis was used to compare the mortality in subgroups ranked by the MELD score. RESULTS: The AUC values generated by the ROC curves for the MELD were 0.85 in predicting 3-month, and 0.78 for 1-year survival respectively, whereas the AUC values for CTP score and for CTP classification were 0.88, 0.81 in predicting 3-month, and 0.76, 0.73 for 1- year survival respectively. The differences of AUCs between the MELD and CTP score and classification were all not significant in predicting above period survival (P 〉 0.05). When the MELD score was greater than 20, the complications of portal hypertensions presented more significantly than that of MELD score less than 20, and the survival time and rate were significantly decreased (P= 0. 000). CONCLUSION: MELD is a good prognosis indictor in patients with primary hepatic cancer for short-term survival. The ability of prognosis of MELD is similar to Child-Turcotte-Pugh score and classification.
出处 《中华肿瘤防治杂志》 CAS 2007年第4期297-299,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 肝肿瘤/治疗 预后 模型 统计学 liver neoplasms/therapy prognosis models statistical
  • 相关文献

参考文献1

二级参考文献26

  • 1Cooper GS,Bellamy P,Dawson NV,Desbiens N,Fulkerson WJ,Goldman L, Quin LM,Speroff T,Landefeld CS.A prognostic model for patients with end-stage liver disease.Gastroenterology 1997;113:1278-1288.
  • 2Wiesner RH,McDiarmid SV,Kamath PS,Edwards EB,Malinchoc M,Kremers WK, Krom RA,Kim WR.MELD and PELD:application of survival models to liver allocation.Liver Transvl 2001:7:567-580.
  • 3Mccaughan GW,Strasser SI.To MELD or not to MELD?Hepatology 2001; 34:215-216.
  • 4Kamath PS,Wiesner RH,Malinchoc M,Kremers W,Therneau TM,Kosberg CL, D'Amico G,Dickson ER,Kim WR.A modelto predict survival in patients with endstage liver disease.Hepatology 2001;33:464-470.
  • 5Malinchoc M,Kamath PS,Gordon FD,Peine CJ,Rank J,ter Borg PCJ.A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.Hetmtology 2000,31:864-871.
  • 6Angermayr B,Koenig F,Cejna M,Karnel F,Gschwantler M,Ferenci P,Gangl A,Peck-Radosavljevic M.Creatinine-modities Child-Pugh score (CPSC) compared with MELD-score to predict survival in patients undergoing TIPS.Hepatology 2002;36:378A.
  • 7Angermayr B,Cejna M,Karnel F,Gschwantler M,Koenig F,Pidlich J, Mendel H,Pichler L,Wichlas M,Kreil A,Schmid M,Ferlitsch A,Lipinski E,Brunner H,Lammer J,Ferenci P,Gangl A,Peck-Radosavljevic M. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portystemic shunt.Gut 2003,52:879-885.
  • 8Moreau R,Lebrec D.Acute renal failure in patients with cirrhosis: perspectives in the age of MELD.Hepatology 2003;37:233-243.
  • 9Nair S,Verma S,Thuluvath PJ.Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002:35:1179-1185.
  • 10DeLong ER,DeLong DM,Clarke-Pearson DL.Comparing the areas under two or more correlated receiving operating characteristics curves:a nonparametric approach.Biometrics 1988;44:837-845.

共引文献31

同被引文献75

  • 1李自微.肝病血清蛋白电泳谱分析[J].中西医结合肝病杂志,2005,15(1):45-46. 被引量:8
  • 2凌昌全,刘庆,李东涛,岳小强,侯凤刚,朱德增,俞超芹,陈喆,翟笑枫,于洋.原发性肝癌常见中医基本证候定性诊断规范的研究[J].中西医结合学报,2005,3(2):95-98. 被引量:77
  • 3乔成栋,张彩云,郭小冬,赵亮,蒋生祥.复方丹参滴丸抗大鼠肝纤维化的实验研究[J].兰州大学学报(医学版),2007,33(1):14-18. 被引量:23
  • 4刘厚钰.原发性肝癌[A].叶任高,陆再英主编内科学[M].北京人民卫生出版社,2004.454.
  • 5Seno H, Ito K, Kojima K, et al. Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5- fluorouracil, epirubicin and mitomycin C [J]. J Gastroenterol Hepatol, 1999,14(8):811-816.
  • 6Sangro B, Bios R, Bilbao J, et al. Efficacy and toxicity of intra- arterial cisplatin and etoposide for advanced hepatocellular carcinoma [J].Oncology, 2002,62 (4) :293-298.
  • 7GARCIA M, JEMAL A, WARD E M, et al. Global cancer facts & figures 2007[R]. Atlanta: American Cancer Society, 2007: 18-23.
  • 8LLOVET J M, BRUIX J. Systematic review of randomized trims for unresectable hepatocellular car- cinoma: chemoembolization improves survival[J]. Hepatoloy, 2003, 37(2): 429-442.
  • 9SEONG J, PARK H C, HANK H, et al. Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with trascatheter arterial chemoembolization[J]. Int J Radiat Oncol Biol Phy, 2000, 47(14): 1331-1335.
  • 10KAMATH P S, WIESNER R H, MALINCHOC M, et al. A model to predict survival in patients with endstage liver disease[J]. Hepatology, 2001, 33(2): 464- 470.

引证文献7

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部